ImmunityBio (NASDAQ:IBRX) Receives Buy Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report issued on Tuesday,Benzinga reports. They currently have a $24.00 price objective on the stock.

IBRX has been the subject of a number of other research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. Jefferies Financial Group increased their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

ImmunityBio Trading Up 8.9%

Shares of NASDAQ:IBRX opened at $2.82 on Tuesday. The stock has a market capitalization of $2.78 billion, a P/E ratio of -6.88 and a beta of 0.03. The stock’s 50-day moving average price is $2.17 and its 200-day moving average price is $2.41. ImmunityBio has a 12-month low of $1.83 and a 12-month high of $4.27.

ImmunityBio (NASDAQ:IBRX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.03. The company had revenue of $32.06 million for the quarter, compared to analysts’ expectations of $31.88 million. As a group, research analysts predict that ImmunityBio will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Slow Capital Inc. bought a new stake in shares of ImmunityBio during the 3rd quarter valued at about $25,000. Truist Financial Corp purchased a new stake in ImmunityBio in the third quarter worth about $27,000. Swiss Life Asset Management Ltd purchased a new stake in ImmunityBio in the third quarter worth about $27,000. Diversify Advisory Services LLC bought a new stake in ImmunityBio during the 2nd quarter valued at approximately $27,000. Finally, Financial Enhancement Group LLC purchased a new position in shares of ImmunityBio during the 2nd quarter worth approximately $28,000. 8.58% of the stock is currently owned by institutional investors.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company data: ImmunityBio reported positive results showing ANKTIVA as a lymphocyte‑stimulating agent when combined with checkpoint inhibitors in NSCLC patients — a clinical signal that could expand ANKTIVA’s utility in immuno‑oncology and supports future trials or partnerships. ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent
• Positive Sentiment: News flow & retail pickup: Financial and consumer outlets highlighted the ANKTIVA update, driving retail attention and headlines that amplified buying interest. Coverage noted the clinical readout as the proximate catalyst for the share move. Why ImmunityBio (IBRX) Is Up 21.0% After New ANKTIVA Immune‑Restoration Data IBRX garners retail attention on positive update
• Positive Sentiment: Analyst support: D. Boral Capital reaffirmed a “buy” and set a $24 price target, highlighting a very large upside vs. current levels — the note likely boosted confidence among momentum and value‑seeking traders. Benzinga coverage of analyst reaffirmation
• Positive Sentiment: Options activity: Unusual activity showed a large spike in call purchases (over 15k calls), which is consistent with bullish speculative positioning and may have amplified intraday upside and gamma-driven buying. (Trading data reported 1/13/2026.)
• Neutral Sentiment: Corporate visibility: ImmunityBio is co-hosting a U.S.-Saudi Biotech Alliance Summit alongside NantWorks at the J.P. Morgan Healthcare Conference — increases corporate visibility and government/partner engagement but is a longer‑term positive rather than an immediate revenue driver. NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit
• Neutral Sentiment: Short interest data reported is inconsistent (showing zero and NaN increases), so there’s no clear short‑squeeze signal from the public data — treat reported short‑interest changes as unreliable until clarified by exchanges or the company.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.